Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period of August 2, 2013, covering an event that occurred on August 1, 2013. The company is a Delaware corporation focused on regenerative medicine, specifically spinal cord-derived neural stem cells.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported. The significant event is scientific in nature: the publication of a paper in the journal Cell Transplantation – The Regenerative Medicine Journal. The study reported that the Company's spinal cord-derived neural stem cells, NSI-566, improved cognitive function in rats that had received radiation to the brain, as assessed by two separate cognitive tasks.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the context of the scientific study. The primary disclosure is the attachment of a press release (Exhibit 99.01) detailing the positive preclinical results.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for details on the study methodology.
- Confirm the publication status and peer-review details of the paper in Cell Transplantation.
- Assess the timeline for potential clinical trials based on these preclinical rat study results.
- Note that the registrant name in the filing is Neuralstem, Inc., distinct from the metadata field "Palisade Bio, Inc."